(BAK) Braskem - Ratings and Ratios
Exchange: NYSE • Country: Brazil • Currency: USD • Type: Common Stock • ISIN: US1055321053
BAK: Resins, Plastics, Chemicals, Fuels, Solvents, Polymers
Braskem S.A., operating under the ticker symbol BAK on the NYSE, stands as a prominent player in the petrochemical industry, specializing in the production of thermoplastic resins. With a market capitalization of approximately $2.223 billion, the companys financial metrics reveal a forward P/E ratio of 9.78 and a price-to-book ratio of 181.02, indicating a unique valuation proposition for investors. Braskems diverse product portfolio encompasses a wide range of chemicals and petrochemicals, including ethylene, propylene, polyethylene, and polypropylene, which are integral to various industrial applications.
Headquartered in São Paulo, Brazil, Braskem was established in 1972 and operates as a subsidiary of Novonor S.A. The companys strategic expansion into Mexico underscores its commitment to broadening its market reach and production capabilities. Braskems operations are not limited to petrochemicals; they also encompass the production of utilities such as steam and industrial gases, showcasing a vertically integrated business model that enhances operational efficiency and cost management.
For investors and fund managers, Braskems position in the commodity chemicals sector, classified under the GICS Sub Industry, offers exposure to a sector critical for global manufacturing and infrastructure development. The companys focus on sustainability and innovation, particularly in green solutions like biodegradable plastics, aligns with growing ESG considerations in investment decisions. Additionally, Braskems feedstock diversification strategy is pivotal in navigating the volatility of raw material costs, a key factor in maintaining profitability in the petrochemical industry.
Braskems role as a supplier to second-generation producers and its extensive product range, including solvents and specialty chemicals, positions it as a crucial link in the supply chain for numerous industries. With a forward-looking approach, Braskem continues to adapt to evolving market dynamics, emphasizing the importance of operational flexibility and strategic investments in technology. This adaptability is crucial for sustaining long-term growth and competitiveness in the global market.
Additional Sources for BAK Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BAK Stock Overview
Market Cap in USD | 2,223m |
Sector | Basic Materials |
Industry | Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception | 1999-01-13 |
BAK Stock Ratings
Growth 5y | -48.4% |
Fundamental | -49.1% |
Dividend | 10.1% |
Rel. Strength Industry | -53.9 |
Analysts | 3.86/5 |
Fair Price Momentum | 3.54 USD |
Fair Price DCF | - |
BAK Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 33.5% |
BAK Growth Ratios
Growth Correlation 3m | -23% |
Growth Correlation 12m | -91.2% |
Growth Correlation 5y | -34.7% |
CAGR 5y | -8.89% |
CAGR/Max DD 5y | -0.11 |
Sharpe Ratio 12m | -1.54 |
Alpha | -65.52 |
Beta | 1.23 |
Volatility | 52.71% |
Current Volume | 670k |
Average Volume 20d | 617k |
As of March 14, 2025, the stock is trading at USD 3.62 with a total of 670,003 shares traded.
Over the past week, the price has changed by -0.55%, over one month by -19.56%, over three months by -15.22% and over the past year by -56.33%.
Probably not. Based on ValueRay Fundamental Analyses, Braskem (NYSE:BAK) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.10 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BAK as of March 2025 is 3.54. This means that BAK is currently overvalued and has a potential downside of -2.21%.
Braskem has received a consensus analysts rating of 3.86. Therefor, it is recommend to buy BAK.
- Strong Buy: 3
- Buy: 1
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, BAK Braskem will be worth about 3.8 in March 2026. The stock is currently trading at 3.62. This means that the stock has a potential upside of +5.8%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.4 | 160.8% |
Analysts Target Price | 9.4 | 160.8% |
ValueRay Target Price | 3.8 | 5.8% |